We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Port Erin | LSE:PEBI | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 4.00 | 5.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMPEBI
RNS Number : 2482C
Port Erin Biopharma Investments Ltd
12 April 2017
12 April 2017
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 31 March 2017
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2017 was 10.56 pence per share, including un-invested cash of GBP3,285. The portfolio is valued under IFRS at bid price.
Net Assets stand at GBP2.50 million including investments of GBP2.49 million. This quarter's NAV represents a decrease of 5.1% from the previous valuation of 11.13 pence per share, which included un-invested cash of GBP66,642. No additional management fee is due to Shellbay Investments Limited.
The reported NAV to 31 March 2017 decreased mainly due to a reduction in the value of the Regent Pacific Group investment which has fallen over the quarter by 27.1%. However, the investment in Magna Biopharma Income Fund has increased by 8.9%. The Company's three principal investments continue to show significant growth prospects for 2017 and beyond.
We have agreed to extend the loan agreement with the Diabetic Boot Company Limited ("DBC"), announced on 22 December 2016, for GBP200,000 to 30 September 2017. The loan pays a coupon of 7%, is unsecured and is fully repayable on the earlier of 30 September 2017 or the date on which DBC secures additional equity funding of GBP1 million. We already hold 7,105 shares in DBC, representing 0.74% of its issued share capital."
Hot Features
Premium
Unaudited to 31 March 2017
GBP
Fixed Assets
Investments 2,294,201
Current Assets
Loan receivable 200,000
Sundry Debtors 8,489
Uninvested cash 3,285
Current Liabilities
Creditors: amounts due (57,333)
--------------------------
2,448,642
Capital and Reserves
Share Capital 23
Share Premium 1,890,142
Reserves 558,477
--------------------------
2,448,642
Shares in Issue 23,195,558
Net Asset Value per share 10.56 pence
Portfolio Details
Investments as at 31 Value % of Total Portfolio March 2017 ------------------------- ------------- -------------------- Magna Biopharma Income Fund GBP1,038,704 41.65% Regent Pacific Group GBP539,496 21.63% Summit Corporation GBP237,770 9.53% Investment loans GBP200,000 8.02% Other quoted holdings GBP131,613 5.28% Other unquoted holdings GBP346,618 13.89% Total GBP2,494,201 100.00% ------------------------- ------------- --------------------
For further information, please contact:
Port Erin Biopharma Northland Capital Partners Peterhouse Capital
Investments Limited Limited Limited
The Company Nomad and Broker Broker
Denham Eke Matthew Johnson / David Lucy Williams
(+44) (0) 1624 639396 Hignell (+44) (0) 207
(+44) (0) 203 861 6625 469 0936
This information is provided by RNS
The company news service from the London Stock Exchange
END
NAVMMGMDVMFGNZM
(END) Dow Jones Newswires
April 12, 2017 02:00 ET (06:00 GMT)
1 Year Port Erin Chart |
1 Month Port Erin Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
